Tiny needle patch takes aim at skin cancer
NCT ID NCT05377905
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This study tests a small adhesive patch with tiny needles that deliver a low dose of the chemotherapy drug doxorubicin directly into skin cancer tumors. It involves 48 people with squamous cell skin cancer who are either immune-competent or immune-suppressed. The goal is to see if the patch is safe and can clear the tumor under and around it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Pittsburgh Medical Center
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
doxorubicin delivered via a microneedle patch
What this could lead to
If it works, this could offer a less invasive, targeted treatment for skin cancer that avoids systemic chemo side effects.
What could go wrong
This is an early-phase trial with only 48 participants, so results may not apply broadly. The patch only treats the area under it, and cancer may still recur elsewhere.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.